Some new evidence in favour of cetuximab in a prospectively selected series of WT-KRAS patients emerged from a very recent study presented at the American Society of Clinical Oncology 2013 Annual Meeting[13]. From this large trial, the combination of cetuximab and FOLFIRI resulted more effective than the combination of bevacizumab and FOLFIRI in a population of WT-KRAS metastatic colon cancer patients, both considering ORR and OS (28.7 mo vs 25 mo).